BioSpace News Archive

BioMidwest

Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event

Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes

November 11, 2018
·
20 min read
Drug Development

Acucela Initiates Phase 3 Study of Emixustat Addressing Patients with Stargardt Disease

Acucela Inc. announced today that on November 7, 2018, the first patient has enrolled (FPFV; first patient first visit) in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride (“emixustat”), in subjects with macular atrophy secondary to Stargardt disease.

November 11, 2018
·
6 min read
Drug Development

Generon Receives Investigative New Drug (IND) Approval from China SFDA for A-319 to Treat Patients with B Cell Malignancies

Generon Corporation today announced it received approval for the Company’s Investigational New Drug (IND) application from the State Food and Drug Administration (SFDA) of the People’s Republic of China to initiate a Phase I clinical trial for A-319 in patients with B cell malignancies.

November 11, 2018
·
3 min read
Biotech Beach

Annenberg PetSpace Waives Adoption Fees In Midst Of Wildfires

LA-Based Adoption Facility Partners with Local Shelters to Make Room for Incoming Pets

November 11, 2018
·
1 min read
Pharm Country

ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause

Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL

November 11, 2018
·
14 min read
Policy

FDA Safety Study of Unloading the Left Ventricle for 30 Minutes Prior to Reperfusion in Heart Attack Patients is Safe and Feasible

Abiomed will initiate pivotal randomized controlled trial with FDA

November 11, 2018
·
7 min read
Pharm Country

New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients

Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker for heart failure severity and prognosis(1)

November 11, 2018
·
17 min read
Biotech Bay

Harpoon Therapeutics Announces Closing of $70M Series C Financing

Proceeds to Advance Pipeline of Cancer Immunotherapies

November 11, 2018
·
3 min read
Business

Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer

Ascletis Pharma Inc. announces today that Dr. Lindi Tan joins Ascletis as Chief Financial Officer.

November 11, 2018
·
1 min read